Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure.
Mueller
Thomas
T
Gegenhuber
Alfons
A
Haltmayer
Meinhard
M
D002316:Cardiotonic Agents / Q000627:therapeutic use*; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D011724:Pyridazines / Q000627:therapeutic use*; D000077464:Simendan
D002316:Cardiotonic Agents; D006835:Hydrazones; D015850:Interleukin-6; D010446:Peptide Fragments; D011724:Pyridazines; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D000077464:Simendan